The Decrease in Serum Bone-Specific Alkaline Phosphatase Predicts Bone Mineral Density Response to Hormone Replacement Therapy in Early Postmenopausal Women

2000 ◽  
Vol 66 (2) ◽  
pp. 104-107 ◽  
Author(s):  
R. Dresner-Pollak ◽  
M. Mayer ◽  
D. Hochner-Celiniker
Keyword(s):  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Early Postmenopausal Women ◽  
Density Response

The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women

Bone ◽  
2007 ◽  
Vol 40 (5) ◽  
pp. 1244-1251 ◽  
Author(s):  
Gianni F. Maddalozzo ◽  
Jeffrey J. Widrick ◽  
Bradley J. Cardinal ◽  
Kerri M. Winters-Stone ◽  
Mark A. Hoffman ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Hormone Replacement Therapy ◽  
Resistance Training ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hormone Replacement ◽  
Spine Bone Mineral Density ◽  
Mineral Density ◽  
Early Postmenopausal Women

Concentration of selected micro-nutrients in saliva among women in menopausal period treated with hormone replacement therapy

2013 ◽  
Vol 22 (01) ◽  
pp. 46-51
Author(s):  
M. Rahnama ◽  
I. Jastrzêbska-Jamrogiewicz ◽  
R. Jamrogiewicz
Keyword(s):  
Bone Mineral Density ◽  
Hormone Replacement Therapy ◽  
Blood Serum ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Surgical Removal ◽  
Femoral Bone ◽  
Mineral Density ◽  
Natural Menopause ◽  
Copper Zinc

Summary Objective: The aim of this study was to observe the variability of the level of copper, zinc and manganese in saliva amongst women with hypoestrogenia, treated and untreated with hormone replacement therapy (HRT). Methods: The study was conducted on a group of 60 women treated and untreated with HRT. Half of the patients were after natural menopause and other half was after surgical removal of ovaries. Research on micronutrients in non-stimulated saliva and blood serum was carried out in 2005. Tests on saliva were repeated in 2010. Investigation of bone mineral density (BMD) of femoral bone was performed in year 2010. Results: Statistical analysis of concentration of copper and zinc revealed a linear correlation between the levels of these microelements in blood serum and saliva. The study revealed that HRT has a beneficial effect on BMD and the concentration of copper and manganese in saliva and blood serum of patients after the menopause. Patients treated with HRT showed higher BMD values than groups not treated with hormones. Conclusions: Saliva appears to be a promising diagnostic material which can be used to analyze the content of trace elements, but further research should be carried out on a broader research group.

scholarly journals Nonassociation of Estrogen Receptor Genotypes with Bone Mineral Density and Estrogen Responsiveness to Hormone Replacement Therapy in Korean Postmenopausal Women

1997 ◽  
Vol 82 (4) ◽  
pp. 991-995 ◽  
Author(s):  
Ki Ok Han ◽  
In Gul Moon ◽  
Young Soon Kang ◽  
Ho Yeon Chung ◽  
Hun Ki Min ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Hormone Replacement Therapy ◽  
Lumbar Spine ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Gene Locus ◽  
Restriction Site ◽  
Hormone Replacement ◽  
Mineral Density

Abstract Hormone replacement therapy (HRT) prevents bone loss in postmenopausal women, but some women are resistant to therapy. A recently reported case of severe estrogen resistance caused by a germ-line mutation at the estrogen receptor (ER) gene locus suggests the possibility that other variants of the ER gene could be responsible for resistance to HRT and could also be an answer to the heritable components of bone density. Three restriction fragment length polymorphisms (RFLPs) at the ER gene locus, represented as BstUI (or B variant), PvuII, and XbaI, and their relationship to bone mineral density (BMD) and estrogen responsiveness to HRT were examined in 248 healthy postmenopausal women, aged 41–68 yr (mean± sd, 52.0 ± 4.6 yr) in Korea. The BstUI restriction site was not found in Korean women. The distribution of the PvuII and XbaI RFLPs was as follows: PP, 35 (14.1%); Pp, 136 (54.8%); pp, 77 (31.1%); and XX, 18 (7.3%); Xx, 72 (29.0%); and xx, 158 (63.7%), respectively (capital letters signify the absence of and lower case letters signify the presence of the restriction site of each RFLP). There was no significant relation between ER genotypes and z score values of lumbar spine BMD. Also, no significant genotypic differences were found in the change in lumbar spine BMD and those in biochemical markers before and after 1 yr of HRT. These data indicate no significant effects of ER genotypes on BMD and estrogen responsiveness after HRT.

scholarly journals Relationship between Inflammatory cytokines and bone mineral density in posmenopausal women with hormone replacement therapy.

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Cristina Carvalho ◽  
Giovana Gonçalves ◽  
Tatiana Bonetti ◽  
Ana Maria Massad‐Costa ◽  
Ismael Guerreiro Silva
Keyword(s):  
Bone Mineral Density ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Inflammatory Cytokines ◽  
Bone Mineral ◽  
Hormone Replacement ◽  
Mineral Density

Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer

2001 ◽  
Vol 19 (14) ◽  
pp. 3306-3311 ◽  
Author(s):  
Charles L. Shapiro ◽  
Judith Manola ◽  
Meryl Leboff
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Adjuvant Chemotherapy ◽  
Bone Loss ◽  
Bone Mineral ◽  
Ovarian Failure ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

PURPOSE: We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal turnover in a prospective longitudinal study of young women with breast cancer receiving adjuvant chemotherapy. PATIENTS AND METHODS: Forty-nine premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated within 4 weeks of starting chemotherapy (baseline), and 6 and 12 months after starting chemotherapy with dual-energy absorptiometry and markers of skeletal turnover osteocalcin and bone-specific alkaline phosphatase. Chemotherapy-induced ovarian failure was defined as a negative pregnancy test, greater than 3 months of amenorrhea, and a follicle-stimulating hormone ≥ 30 MIU/mL at the 12-month evaluation. RESULTS: Among the 35 women who were defined as having ovarian failure, highly significant bone loss was observed in the lumbar spine by 6 months and increased further at 12 months. The median percentage decrease of bone mineral density in the spine from 0 to 6 months and 6 to 12 months was −4.0 (range, −10.4 to +1.0; P = .0001) and −3.7 (range, −10.1 to 9.2; P = .0001), respectively. In contrast, there were no significant decreases in bone mineral density in the 14 patients who retained ovarian function. Serum osteocalcin and bone specific alkaline phosphatase, markers of skeletal turnover, increased significantly in the women who developed ovarian failure. CONCLUSION: Chemotherapy-induced ovarian failure causes rapid and highly significant bone loss in the spine. This may have implications for long-term breast cancer survivors who may be at higher risk for osteopenia, and subsequently osteoporosis. Women with breast cancer who develop chemotherapy-induced ovarian failure should have their bone density monitored and treatments to attenuate bone loss should be evaluated.

Sign in / Sign up

Export Citation Format

Share Document